Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | PAB1-binding protein , putative | 0.0009 | 0 | 0.5 |
Loa Loa (eye worm) | D-ets-4 DNA binding domain-containing protein | 0.0037 | 0.2675 | 0.2675 |
Loa Loa (eye worm) | TAR-binding protein | 0.0036 | 0.2613 | 0.2613 |
Brugia malayi | Ets-domain containing protein | 0.0037 | 0.2675 | 0.2675 |
Schistosoma mansoni | ets-related | 0.0112 | 1 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0009 | 0 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0036 | 0.2613 | 0.2613 |
Loa Loa (eye worm) | fli-1 protein | 0.0112 | 1 | 1 |
Echinococcus multilocularis | GA binding protein alpha chain | 0.0037 | 0.2675 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0009 | 0 | 0.5 |
Brugia malayi | RNA binding protein | 0.0036 | 0.2613 | 0.2613 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0036 | 0.2613 | 0.2613 |
Loa Loa (eye worm) | RNA binding protein | 0.0036 | 0.2613 | 0.2613 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0009 | 0 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0009 | 0 | 0.5 |
Brugia malayi | Ets-domain containing protein | 0.0037 | 0.2675 | 0.2675 |
Leishmania major | hypothetical protein, conserved | 0.0009 | 0 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0009 | 0 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0036 | 0.2613 | 0.2613 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0009 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.2153 | 0.2153 |
Schistosoma mansoni | gabp alpha | 0.0037 | 0.2675 | 0.0084 |
Echinococcus granulosus | GA binding protein alpha chain | 0.0037 | 0.2675 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.